Complexities, pitfalls, and strategies for evaluating brain tumor therapies
Richard S. Kaplan · Current Opinion in Oncology · 1998
Because there are no highly reliable and predictive animal models of human gliomas, it is necessary to carry out both preliminary investigation and definitive testing of new treatments in a clinical setting. Efficient and accurate estimation of the clinical value of potential new cancer therapies is often quite challenging, and oncologists have standardized some methodologies for this purpose. There are some special difficulties with regard to investigating treatments for brain tumor patients, however, and these may be magnified in the near future by the novel mechanisms of action of the most exciting classes of drugs in development.